Curis to Present at Roth Capital Partners New York Conference; CEO Presentation to Be Webcast Live.CAMBRIDGE, Mass. -- Curis, Inc. (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on : CRIS) announced today that Daniel Passeri, Curis' President and Chief Executive Officer, will speak at the upcoming Roth Capital Partners Roth Capital Partners, LLC, is a full service Investment Banking firm, specializing in the small and micro cap markets. Roth’s focus, according to its official website, "has been, is, and will continue to be providing the full spectrum of investment banking services, New York New York, state, United States New York, Middle Atlantic state of the United States. It is bordered by Vermont, Massachusetts, Connecticut, and the Atlantic Ocean (E), New Jersey and Pennsylvania (S), Lakes Erie and Ontario and the Canadian province of Conference to be held on September 13-15, 2004, at the St. Regis Hotel in New York City New York City: see New York, city. New York City City (pop., 2000: 8,008,278), southeastern New York, at the mouth of the Hudson River. The largest city in the U.S. . Mr. Passeri's presentation is scheduled for 8:00 AM EST EST electroshock therapy. EST abbr. electroshock therapy on Wednesday, September 15th. He will present an update on the status of Curis' business, including information with respect to its collaborations, product candidate development, and expected year-end cash position. The presentation will be webcast live at: http://www.wsw.com/webcast/roth4/cris/ It will also be archived at the same address for thirty days after the presentation. The presenting companies, many of whom received top honors from prestigious publications over the past year, have been hand picked by Roth Capital Partners' research team. The conference will feature presentations from more than 200 public companies. Last year's New York conference showcased 94 companies to an audience of over 650 institutional investors. About Curis, Inc. Curis, Inc. is a therapeutic drug development company. The Company's technology focus is on regulatory pathways that control repair and regeneration. Curis' product development involves the use of proteins or small molecules to modulate these pathways. Curis has successfully used this technology and product development approach to produce several promising drug product candidates in the fields of kidney disease (partnered with Ortho Biotech, a subsidiary of Johnson & Johnson), cancer (partnered with Genentech), neurological disorders (partnered with Wyeth Pharmaceuticals), alopecia alopecia (ăl'əpē`shēə): see baldness. , and cardiovascular disease. For more information, please visit the Curis web site at www.curis.com. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion